# Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain

> **NCT00904397** · PHASE4 · TERMINATED · sponsor: **Endo Pharmaceuticals** · enrollment: 98 (actual)

## Conditions studied

- Chronic Low Back Pain

## Interventions

- **DRUG:** Lidoderm®
- **DRUG:** Celecoxib

## Key facts

- **NCT ID:** NCT00904397
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-07
- **Primary completion:** 2004-11
- **Final completion:** —
- **Target enrollment:** 98 (ACTUAL)
- **Why stopped:** Rofecoxib was withdrawn from the market due to safety concerns.
- **Last updated:** 2010-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00904397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00904397, "Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00904397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*